Sun, Nov 23, 2014, 3:27 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

PatientMD 11 posts  |  Last Activity: Nov 8, 2014 12:44 AM Member since: Jan 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Investors response to the "big news" about settlement seems to have been rather lukewarm. Millions of shares traded and up less than 1dollar. Previously bad news as predicted caused sig drop in pps.
    Has Wall Street lost enthusiasm with company's prospects and sluggish
    Growth rate in revenues and profit? Too much money spent on lawsuit for this result? What do we wait for now? Earnings surprise? TISA suit?
    Who bought today and who sold? Why no squeeze? Disappointed!!!!

    Sentiment: Hold

  • The above statement on tisa's webpage about suit settlement. how accurate?
    can someone with tech saavy tell me how there tech different form mitek's and is it better or more suited to financial institutions? they also say that they are going global and going to try and penetrate us market.
    in summary, other than saving money on lawsuits and having that suit overhang the company and effect potential buy out, was this a "win" for mitek or a loss ?
    are they a competitor to fear in the future or are they "pumping" their technology beyond reason? value of mitek patent portfolio?

    Sentiment: Hold

  • mitek continues to drift downward daily despite natural variance in markets. Has the market lost complete
    faith in management and the company's prospects? despite positive press releases, does the market
    view this as merely "pumping" up prospects or does the market and those that count in this arena have a more optimistic view of the future of mobile transactions but view mitek as a flawed participant with limited prospects? can the business model be changed to increase revenues and profits? is the patent portfolio worthy and maybe enticing to another company or is its significance been exaggerated? are there competitors with more clout or at least with more resources and a better image on the street? the settlement of the law suits obviously was not what some expected or hoped for but with those expenses decreased will there be chance for profitability or will there be more suits and more expenses?

    before, I absorb the criticism that the above questions will generate, let me say that I have been long in this company and continue to be so; however, these are the questions and the fears that are bouncing around in my head and eroding my initial optimism as the stock continues its daily slide. I hope some on board
    with more insight will provide "valuable" input which may either reinforce my position and hopes or weaken them.

  • patientmd patientmd Nov 4, 2014 6:05 PM Flag

    unfortunately, I have been a shareholder for over 10 years and have seen the "red flags" before with the
    drop in share price prior to an announcement, which in every case has been "bad news" with failures of phase 3 results when positive news was expected confirming fact there are no secrets except those from the smaller investors. I hope gog..... is wrong about this one and the news is positive. Will wait nervously for tomorrow's announcement and hope that management have complied with all FDA's requests and no more delays ( over 2 years now)

    Sentiment: Hold

  • Reply to

    One last thought on delay...and halt...

    by upsidefz Nov 5, 2014 7:27 PM
    patientmd patientmd Nov 5, 2014 8:11 PM Flag

    unfortunately, wrong!! Bumped up sales force before as well as hiring more management only to fall flat on face when the prostate drug and then the colon cancer drug failed phase 3

  • 3x and your out; this is third time that management failed miserably to deliver results promised; this is worst with the letter from the FDA indicating that time and money wasted for past 3 years all the time either misinterpreting the results of studies and communication with FDA or misrepresenting them; No matter,
    do not believe anything company states anymore and truly believe that because of this THERE IS NO VIABLE PIPELINE and that there will be lawsuit which they will not be able to defend ( not able to defend their bonuses and salaries either). 8M shares traded 2 days ago. We shareholders in small companies have no chance with either the leak at the company level or the FDA and this should also be investigated and if the latter FDA should be accountable for losses ( fat chance) if someone there is leaking to the investing public prior to bad news.

  • Anyone on this board believe management can manage and/or deliver on any drug??? Either through misinterpretation and bad advice or more worrisome misrepresentation of the facts, despite positive PR they have failed miserably 3x. Therefore, I believe that there is no viable pipeline!!!!!!! However, they will pursue
    development of it as long as there are funds for their salaries and bonuses. Save the 43M and divide it among the shareholders.
    I have lost a lot of $$ on this long trek to nowhere ( thank goodness they spun off the vitamin company and it paid well). They never intended to develop Macrilen but were forced to when the colorectal drug failed.
    How could they have moved forward and spent time and money past 3 years in the face of such a condemnation from the FDA? So many flaws could not or should not have been a surprise.

    There is no way the company can make lemonade from this lemon announcement. The bitter taste will last a long time. Still not sure why 8M shares traded day before announcement. Were these who sold lucky?
    Clairvoyant? Or privy to information from FDA or company that rest of us did not have?
    Investigation needs to be done and all held accountable.

    Sentiment: Strong Sell

  • I hope some analyst or private investor(although I bet won't be given the chance by company to ask)
    has the guts to ask " in view of the harsh CRL by FDA yesterday it seems that the company spent 2 years and considerable resources trying to get approval of drug that never had a chance based on company's phase 3,
    why???? Secondly, with your track record which includes Marcrilen and the last 2 surprises of prostate drug and colorectal drug ( maybe they weren't such surprises) how can we trust the company to intelligently
    plan drug phase trials, accurately assess the results, and honestly report to the investing community???.
    If we all have lost confidence, the pipeline which continually is shrinking is imaginary and worthless.
    Management needs to take bold initiative like suspending bonuses, options and even reducing salaries until they actually perform.

    Sentiment: Sell

  • Since it seems that the sales force hired for Macrilen was linked to Ascend's sales reps, what does the future hold?? Why would Ascend tie its future to a company like AEZS at this time? Wouldn't count on it!!!

    Sentiment: Sell

  • During CC, current management shifted responsibility of purchasing rights to Marilen on previous management team who apparently reviewed and liked phase 2 studies done by another company.
    Current management unclear and shifted to one another but it appears that they accepted phase 2 studies done elsewhere and did not do due exhaustive review of their own before starting phase 3. This does not seem like an appropriate course of action.
    To make things worse, after phase 3 data in ( over 2 years ago) why didn't the FDA review the results
    and point out the tragic flaws of the phase 2 and 3 studies before encouraging or permitting AEZS to go forward with the time consuming, costly, diluting process to obtain NDA? The last 2 years were a total waste of resources and time and never should have occurred if the FDA would have acted responsibility and alerted the company to the flaws. Approval never had a chance.
    So who to blame for this fiasco???? Current management for pushing forward without really determining the validity of previous studies and accepting previous management's assessment.!! The FDA for not providing the guidance necessary to halt process of seeking approval.
    The losers, we shareholders again!!!!!!!!
    How much of us have confidence that AEZS can plan and carryout a successful phase 3 on endometrial cancer drug????

    Sentiment: Sell

  • Better than expected good news and the response of stock disappointing! Explanation?
    What is it going to take to have this stock make a sig move upwards? How does stock counter the grip the shorts seem to have? Bad news pummels the stock and yet good news barely moves it.

    Sentiment: Buy

0.533+0.0030(+0.57%)Nov 21 3:58 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GameStop Corp.
NYSEFri, Nov 21, 2014 4:04 PM EST
Celgene Corporation
NasdaqGSFri, Nov 21, 2014 4:00 PM EST